This site requires JavaScript to work correctly. Please enable Javascript and reload the page.
EU leaders blindsided on Biden proposal to suspend patents on COVID-19 vaccines, as industry reacts in anger 06 May 2021 | News
Head of EU pharma trade body says waiver would ‘open the door to counterfeit vaccines’ and kill incentives to tackle dangerous virus variants. ‘Who will make the vaccine next time?’ one pharma chief asks
European Commission president, Ursula Von der Leyen. Photo: European Commission
EU leaders on Thursday declined to follow US President Joe Biden and come out in favour of waiving intellectual property protections for COVID-19 vaccines, but did agree to discuss the proposal.
Industry weary of waiving vaccine patents
Sharing excess production and supporting the COVAX program are faster ways to get COVID-19 vaccines to people than removing patent protection, says Nathalie Moll from the European Federation of Pharmaceutical Industries and Associations.
Watch video
03:19
The European Federation of Pharmaceutical Industries and Associations
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, and in collaboration with health and research players, EFPIA’s mission is to create an environment that enables our members to discover, innovate, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
We have a dynamic Public Affairs team working on outreach and coordination of external advocacy on specific policy files and legislative proposals; focusing on the European Parliament, Council, Commission and external stakeholders.
Explainer: Why is India calling for IP rules around Covid vaccines to be waived?
The World Trade Organization will meet again today to discuss the proposal. By Ian Curran Friday 30 Apr 2021, 6:30 AM 4 hours ago 13,637 Views 14 Comments
A mess cremation of Covid-19 victims in New Delhi.
Image: SIPA USA/PA Images
A mess cremation of Covid-19 victims in New Delhi.
Image: SIPA USA/PA Images
AS VIRUS CASES and death tolls linked to Covid-19 continue to spiral in the global South, particularly in India, the World Trade Organization will meet today basis to discuss a proposal to waive intellectual property (IP) rules around vaccines.
Presence of various filtration techniques such as ultrafiltration, nanofiltration and microfiltration under membrane technology has increased its acceptance in pharmaceutical, biopharmaceutical and life science industries for separation and purification of components and biomolecules, over conventional techniques.
However, the market faces some restraints such as effects of membrane fouling, high operational and investment cost and limitation of membrane materials. As a result, the market is expected to grow at a
CAGR of about
9.1% during 2014-2019.
North America is the largest market for membrane technology in pharmaceutical, biopharmaceutical and life sciences industries. The U.S. is the world’s largest market for pharmaceutical and biopharmaceutical products. According to the European Federation of Pharmaceutical Industries and Associations, North America accounted for about 41% of global pharmaceutical sales in 2012.